Prolonged response to first-line erlotinib for advanced lung adenocarcinoma
<p>Abstract</p> <p>A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiatio...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2008-11-01
|
| Series: | Journal of Experimental & Clinical Cancer Research |
| Online Access: | http://www.jeccr.com/content/27/1/59 |
| _version_ | 1811247999141019648 |
|---|---|
| author | Copeman Michael |
| author_facet | Copeman Michael |
| author_sort | Copeman Michael |
| collection | DOAJ |
| description | <p>Abstract</p> <p>A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiation because of toxicity concerns, but agreed to oral erlotinib 150 mg/day. Within weeks, her pain was well controlled, with softening of palpable neck nodes. Repeat scans after 7 months on erlotinib showed partial response of thoracic disease and nodal metastases. This response was maintained for 11 months on erlotinib, with symptomatic progression at the original sites of relapse by 15 months. Erlotinib was well tolerated, with grade 2–3 rash, and grade 1 dry cough and diarrhoea being the only significant toxicities. Importantly, the patient was able to maintain daily activities throughout erlotinib therapy.</p> |
| first_indexed | 2024-04-12T15:19:23Z |
| format | Article |
| id | doaj.art-3e99fb4520d54b51afc01272a4a78208 |
| institution | Directory Open Access Journal |
| issn | 1756-9966 |
| language | English |
| last_indexed | 2024-04-12T15:19:23Z |
| publishDate | 2008-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Experimental & Clinical Cancer Research |
| spelling | doaj.art-3e99fb4520d54b51afc01272a4a782082022-12-22T03:27:29ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662008-11-012715910.1186/1756-9966-27-59Prolonged response to first-line erlotinib for advanced lung adenocarcinomaCopeman Michael<p>Abstract</p> <p>A 58-year-old, non-smoking female of Philippine origin presented with painful thoracic and neck nodal relapse of lung adenocarcinoma almost 5 years after left pneumonectomy for stage II non-small-cell lung cancer. She refused conventional chemotherapy or radiation because of toxicity concerns, but agreed to oral erlotinib 150 mg/day. Within weeks, her pain was well controlled, with softening of palpable neck nodes. Repeat scans after 7 months on erlotinib showed partial response of thoracic disease and nodal metastases. This response was maintained for 11 months on erlotinib, with symptomatic progression at the original sites of relapse by 15 months. Erlotinib was well tolerated, with grade 2–3 rash, and grade 1 dry cough and diarrhoea being the only significant toxicities. Importantly, the patient was able to maintain daily activities throughout erlotinib therapy.</p>http://www.jeccr.com/content/27/1/59 |
| spellingShingle | Copeman Michael Prolonged response to first-line erlotinib for advanced lung adenocarcinoma Journal of Experimental & Clinical Cancer Research |
| title | Prolonged response to first-line erlotinib for advanced lung adenocarcinoma |
| title_full | Prolonged response to first-line erlotinib for advanced lung adenocarcinoma |
| title_fullStr | Prolonged response to first-line erlotinib for advanced lung adenocarcinoma |
| title_full_unstemmed | Prolonged response to first-line erlotinib for advanced lung adenocarcinoma |
| title_short | Prolonged response to first-line erlotinib for advanced lung adenocarcinoma |
| title_sort | prolonged response to first line erlotinib for advanced lung adenocarcinoma |
| url | http://www.jeccr.com/content/27/1/59 |
| work_keys_str_mv | AT copemanmichael prolongedresponsetofirstlineerlotinibforadvancedlungadenocarcinoma |